Viking Therapeutics, Inc.
VKTX
$24.99
-$0.67-2.61%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -128.24M | -109.96M | -99.15M | -96.75M | -93.72M |
| Total Depreciation and Amortization | 383.00K | 346.00K | 310.00K | 296.00K | 294.00K |
| Total Amortization of Deferred Charges | 90.00K | 94.00K | 96.00K | 74.00K | 88.00K |
| Total Other Non-Cash Items | 15.43M | 12.37M | 12.11M | 9.56M | 10.57M |
| Change in Net Operating Assets | -21.65M | 9.36M | 12.38M | 14.87M | 27.90M |
| Cash from Operations | -133.99M | -87.79M | -74.25M | -71.95M | -54.87M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -30.33M | -553.37M | -524.22M | -562.65M | -641.08M |
| Cash from Investing | -30.33M | -553.37M | -524.22M | -562.65M | -641.08M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 6.78M | 654.57M | 653.75M | 651.23M | 920.77M |
| Repurchase of Common Stock | 0.00 | -42.10M | -42.10M | -42.18M | -47.58M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 37.00K |
| Cash from Financing | 6.78M | 612.46M | 611.65M | 609.06M | 873.23M |
| Foreign Exchange rate Adjustments | -99.00K | -148.00K | -24.00K | -63.00K | -69.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -157.64M | -28.84M | 13.16M | -25.60M | 177.22M |